These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: CI-960 (PD127391 or AM-1091), sparfloxacin, WIN 57273, and isepamicin activity against clinical isolates of Mycobacterium avium-intracellularae complex, M. chelonae, and M. fortuitum.
    Author: Barrett MS, Jones RN, Erwin ME, Koontz FP.
    Journal: Diagn Microbiol Infect Dis; 1992 Feb; 15(2):169-71. PubMed ID: 1315233.
    Abstract:
    A 7H9 broth microdilution method against CI-960, sparfloxacin, WIN57273, ciprofloxacin, norfloxacin, isepamicin, amikacin, kanamycin, ethambutol, isoniazid, and rifampin was used to test 35 Mycobacterium avium-intracellulare complex (MAI) and five M. chelonae-fortuitum strains. The majority of MAI isolates were inhibited by all tested compounds, with sparfloxacin (MIC90, 0.5 micrograms/ml) being the most active among the fluoroquinolones; isepamicin (MIC90, 4 micrograms/ml), the most potent aminoglycoside; and isoniazid, rifampin, and ethambutol also demonstrating some degree of activity. Mycobacterium chelonae strains were resistant to all drugs except ciprofloxacin (MIC50, 1 microgram/ml). Mycobacterium fortuitum isolates were generally susceptible, especially to the newer fluoroquinolones.
    [Abstract] [Full Text] [Related] [New Search]